Boston Scientific Acquires Penumbra at $374 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy BSX?
Source: Benzinga
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 58.450
Low
94.00
Averages
108.14
High
132.00
Current: 58.450
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Shares Drop 3.4% Following Downgrade
- Stock Price Decline: Boston Scientific (BSX) shares fell 3.4% during Wednesday afternoon trading, indicating market concerns about the company's future performance, which could impact investor confidence and lead to short-term capital outflows.
- Rating Downgrade Impact: The decline in stock price is linked to a downgrade by Daiwa Securities, suggesting that the market's sensitivity to analyst opinions may have exacerbated the stock's volatility, highlighting investors' heavy reliance on external ratings.
- Market Reaction: The drop in stock price could affect Boston Scientific's market capitalization, which in turn may impact its financing capabilities and future investment plans, especially in the context of intense competition in the medical device industry.
- Investor Sentiment: Changes in analyst ratings often trigger fluctuations in market sentiment, and Boston Scientific needs to take measures to restore investor confidence to avoid further declines in stock price.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's stock plummeted 17.6% to $75.50 per share on February 4, 2026, following disappointing Q4 and full-year 2025 results, particularly in U.S. electrophysiology sales, resulting in significant investor losses.
- False Statements Allegation: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the unsustainable growth rate of its electrophysiology segment and the impact of new competitors, misleading investors about the company's prospects.
- Investor Action Required: Affected investors must file a lead plaintiff motion by May 4, 2026, to pursue claims under federal securities laws, highlighting the urgency and significance of legal action for recovery of losses.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP for legal support, ensuring their rights and interests are protected.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious governance concerns.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division for Q4 2025 and issued fiscal year 2026 guidance that significantly missed analyst expectations, reflecting pressures from slower market growth and increased competition.
- Significant Stock Drop: Following the earnings report, Boston Scientific's stock plummeted by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, indicating strong investor concerns regarding the company's future outlook.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, suggesting that this case could have broader legal and financial implications.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, highlighting serious concerns over the company's financial health.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management provided overly optimistic statements while concealing the true state of its U.S. EP segment's growth, resulting in a significant loss of investor confidence and a stark contrast between management's claims and market expectations.
- Performance Miss Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, leading to a net income miss and a dramatic stock price drop of approximately 17.6%, from $91.62 to $75.50 in a single day, directly affecting investor sentiment and market performance.
- Legal Action Deadline: Shareholders must register for the class action by May 4, 2026, as failure to do so may result in the loss of their right to claim, underscoring the importance of legal processes in protecting shareholder rights.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose qualified law firms with proven success in leadership roles to ensure they receive the best representation in the class action, avoiding firms that merely act as intermediaries.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
Boston Scientific Shares Drop 3.4% Following Downgrade
- Stock Price Decline: Boston Scientific (BSX) shares fell 3.4% during Wednesday afternoon trading, indicating market concerns about the company's future performance, which could impact investor confidence and lead to short-term capital outflows.
- Rating Downgrade Impact: The decline in stock price is linked to a downgrade by Daiwa Securities, suggesting that the market's sensitivity to analyst opinions may have exacerbated the stock's volatility, highlighting investors' heavy reliance on external ratings.
- Market Reaction: The drop in stock price could affect Boston Scientific's market capitalization, which in turn may impact its financing capabilities and future investment plans, especially in the context of intense competition in the medical device industry.
- Investor Sentiment: Changes in analyst ratings often trigger fluctuations in market sentiment, and Boston Scientific needs to take measures to restore investor confidence to avoid further declines in stock price.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's stock plummeted 17.6% to $75.50 per share on February 4, 2026, following disappointing Q4 and full-year 2025 results, particularly in U.S. electrophysiology sales, resulting in significant investor losses.
- False Statements Allegation: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the unsustainable growth rate of its electrophysiology segment and the impact of new competitors, misleading investors about the company's prospects.
- Investor Action Required: Affected investors must file a lead plaintiff motion by May 4, 2026, to pursue claims under federal securities laws, highlighting the urgency and significance of legal action for recovery of losses.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP for legal support, ensuring their rights and interests are protected.
See More
Boston Scientific Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Boston Scientific, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 4, 2026, highlighting serious governance concerns.
- Disappointing Earnings Report: On February 4, 2026, Boston Scientific reported lower-than-expected sales in its electrophysiology division for Q4 2025 and issued fiscal year 2026 guidance that significantly missed analyst expectations, reflecting pressures from slower market growth and increased competition.
- Significant Stock Drop: Following the earnings report, Boston Scientific's stock plummeted by $16.12, or 17.6%, closing at $75.50 on February 4, 2026, indicating strong investor concerns regarding the company's future outlook.
- Legal Firm's Reputation: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, suggesting that this case could have broader legal and financial implications.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, highlighting serious concerns over the company's financial health.
- Allegations of Misrepresentation: The complaint alleges that Boston Scientific's management provided overly optimistic statements while concealing the true state of its U.S. EP segment's growth, resulting in a significant loss of investor confidence and a stark contrast between management's claims and market expectations.
- Performance Miss Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, leading to a net income miss and a dramatic stock price drop of approximately 17.6%, from $91.62 to $75.50 in a single day, directly affecting investor sentiment and market performance.
- Legal Action Deadline: Shareholders must register for the class action by May 4, 2026, as failure to do so may result in the loss of their right to claim, underscoring the importance of legal processes in protecting shareholder rights.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose qualified law firms with proven success in leadership roles to ensure they receive the best representation in the class action, avoiding firms that merely act as intermediaries.
See More
Jim Cramer's Insights on Various Stocks
- Joby Aviation Risk Assessment: Joby Aviation is deemed too risky, with analysts advising new investors to be cautious to avoid disappointment from potential stock price drops, which could hinder its ability to attract new investors.
- BillionToOne Potential: Despite the overall poor performance of diagnostic companies, BillionToOne is viewed as a potential winner, with analysts believing its future performance is promising, which may draw more investor interest in its stock.
- Boston Scientific Competitive Pressure: Boston Scientific faces intense competition, with analysts noting that its market position is under threat; however, there is still potential for a rebound, prompting investors to watch for a price bottom before deciding to buy.
- Rocket Lab Investment Opportunity: Rocket Lab is considered a speculative stock worth investing in, with analysts optimistic about its future performance, especially leading up to the SpaceX IPO, which could attract more speculative investments.
See More
